Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
CDKN1C
REST API REST API
Homo sapiens
CDKN1C is differentially expressed in 375 experiments: 136 organism parts: liver, placenta, ... (134 more);, 229 disease states: normal, control, ... (227 more);, 126 cell types 409 cell lines 59 compound treatments and 81 other conditions.
Synonyms BWCR, P57, BWS, KIP2
Orthologs Cdkn1c (Mus musculus)   Q2HJM8_BOVIN (Bos taurus)   E9PTV7_RAT (Rattus norvegicus)   (Compare orthologs)
Gene Ontology Term negative regulation of transcription, DNA-dependent, protein binding, cytoplasm, negative regulation of cell proliferation, regulation of cyclin-dependent protein kinase activity, cell cycle arrest, G1 phase of mitotic cell cycle, positive regulation of transforming growth factor beta receptor signaling pathway, cell cycle, nucleus, negative regulation of transcription from RNA polymerase II promoter, cyclin-dependent protein kinase inhibitor activity, negative regulation of epithelial cell proliferation, positive regulation of transcription, DNA-dependent, neuron maturation, negative regulation of kinase activity, protein kinase inhibitor activity, negative regulation of phosphorylation
InterPro Term CDI
UniProt Accession P49918, A6NK88
Gene-Disease Assocation BECKWITH-WIEDEMANN SYNDROME; BWS
Search EB-eye ENSG00000129757
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-17189, E-GEOD-803, E-GEOD-15765, E-MEXP-433, E-GEOD-7540, ... (33 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, E-GEOD-18005, ... (45 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-20081, E-GEOD-5823, E-GEOD-3529
BT474
2
E-MTAB-62, E-MEXP-440
T84
2
E-MTAB-37, E-GEOD-1474
A549
2
E-GEOD-3202, E-GEOD-6013
LNCaP
2
E-GEOD-14990, E-GEOD-14464
MCF-10A
2
E-TABM-420, E-GEOD-14990
403 more value(s).


Cell type

studied in E-GEOD-492, E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, ... (63 experiments)

Factor Value U/D Experiments
fibroblast
3
E-GEOD-3204, E-MEXP-466, E-GEOD-3920
adipocyte
2
E-AFMX-5, E-MTAB-25
CD56+ NK cells
2
E-AFMX-5, E-TABM-145
CD8+ T cell
2
E-AFMX-5, E-MTAB-25
embryonic stem cell
2
E-MEXP-930, E-GEOD-2248
CD14+ monocyte
1
2
E-AFMX-5, E-MEXP-1600, E-TABM-145
120 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-MEXP-1121, E-GEOD-1577, ... (75 experiments)

Factor Value U/D Experiments
prostate carcinoma
1
4
E-GEOD-96, E-MEXP-2034, E-MTAB-62, E-MEXP-1327, E-TABM-26 ... (5 experiments)
benign prostatic hyperplasia
3
E-MEXP-2034, E-MEXP-1243, E-GEOD-5377
colon carcinoma
3
E-MTAB-62, E-MTAB-37, E-GEOD-3726
lung adenocarcinoma
3
E-GEOD-2514, E-MTAB-62, E-MEXP-231
uterine fibroid
3
E-MTAB-62, E-GEOD-7307, E-GEOD-2724
control
2
4
E-GEOD-21912, E-GEOD-8121, E-GEOD-16728, E-GEOD-20295, E-GEOD-16363, ... (6 experiments)
223 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-5741, E-TABM-782, E-GEOD-697, E-GEOD-3720, ... (36 experiments)

Factor Value U/D Experiments
none
7
10
E-TABM-782, E-MEXP-1601, E-MEXP-2285, E-MEXP-1269, E-GEOD-20719, ... (17 experiments)
5-aza-2'-deoxycytidine + trichostatin A
1
2
E-GEOD-5230, E-MEXP-1269
lipopolysaccharide
2
E-GEOD-3720, E-TABM-868
control
2
E-GEOD-3284, E-GEOD-5339
Cxcl12
1
E-GEOD-7307
FLAP
1
E-GEOD-3202
53 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519


Biosource provider
studied in E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

cd1a
studied in E-GEOD-22601

cd38
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-GEOD-1729

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-GEOD-1140, ... (12 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-5999, E-GEOD-1614, E-MEXP-2359, E-GEOD-6236, E-GEOD-4667, ... (7 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-22544, E-GEOD-3325, E-TABM-147, E-GEOD-21138, ... (8 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1518, E-GEOD-3720

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011, E-MTAB-73, E-GEOD-7578, E-GEOD-17385, ... (9 experiments)

Genotype
studied in E-GEOD-2152, E-GEOD-2466, E-GEOD-17476, E-GEOD-22593, E-TABM-868, ... (17 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-20540, E-GEOD-22278, E-GEOD-10315, E-GEOD-837, ... (16 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-MEXP-1956, E-MEXP-2069, ... (33 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-6802, ... (7 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-22056, E-GEOD-12662

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-1309, E-GEOD-22309, E-GEOD-21750, E-GEOD-1657, E-GEOD-17636, ... (8 experiments)

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246 ... (5 experiments)

Qrt pcr areg dct
studied in E-GEOD-5851

Replicate
studied in E-GEOD-10797, E-GEOD-10896

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, ... (8 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-17400, E-GEOD-18995

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-2466, E-GEOD-7307, E-GEOD-16363

Sirna
studied in E-GEOD-21575, E-GEOD-21574

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11886

Stimulus or stress
studied in E-GEOD-7538

Strain or line
studied in E-MEXP-1996, E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

tissue (organ)
studied in E-GEOD-22601

Transfection
studied in E-GEOD-14680

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-21909, E-GEOD-19246, E-GEOD-19136, ... (8 experiments)

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments 00 005
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-89, E-GEOD-3494, E-GEOD-4922

Tumor size
studied in E-GEOD-4922

Processing time: 0.374 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM